Cash and Favors: Robert Klein Gives $21,630 to the California Stem Cell Agency
By Dr. Matthew Watson
A seemingly innocuous $21,630 gift to
the California stem cell agency has kicked up new questions about a
controversial $20 million research award and generated a wave of
special favors for the donor that stretched out to include a gold
mining multimillionaire from Canada.
![]() |
Robert Klein Elie Dolgin/Nature photo |
The gift was made last May by Robert
Klein, chairman of the stem cell agency from 2004 to July 2011, but has never
been publicly reported to the agency's governing board as required by
its own regulations.
reviewers of a $20 million application by StemCells, Inc., of Newark, Ca. The board subsequently asked for a reevaluation of the proposal, which was again rejected by reviewers. Klein persisted at a September meeting, and the 29-member board decided, on a 7-5 vote, to go along with him. It was the
first time in its eight-year history that the board has approved an
application that was rejected twice by its scientific reviewers, who scored the proposal at 61 out of 100.
Klein's donation triggered a number of
special favors from the agency, according to documents provided by CIRM to the California Stem Cell Report under a state Public Records Act request. Klein wanted to meet with the six science officers, who have a wide range of responsibilities, including managing and developing grant and loan programs, participating in reviews of applications and evaluating research progress. CIRM President Alan Trounson obliged. At the meeting in Japan, the six science officers received a memo approved by Trounson instructing them to meet
privately “one-on-one” with their benefactor and to give him special access to their activities. The meetings were
actually scheduled to also include a third person, Rob McEwen, who is one of the 100 richest persons in Canada, a $20 million donor to a stem
cell center in Toronto and CEO of the gold mining company bearing his name.
The memo indicated
that the science officers – all California state employees –
should be helpful by identifying areas of “special importance” to
Klein and “other donors.” The CIRM documents show no objection
from the agency to instructions from another member of the public --
Klein aide Melissa King -- to provide her and Klein with written
summaries about the science officers' activities at the convention
along with “details” about their work at CIRM. Email addresses of
the six were also provided to Klein, who may have additionally
received their cell phone numbers although that is not entirely
clear.
invited McEwen to a closed-door session in Japan involving the
agency's international partners, a session at which presumably
valuable, little known scientific information might be mentioned and
future directions charted. Trounson specifically told McEwen in an
email that it was Klein who asked that the executive be invited to the
session.
wrongdoing in connection with the donation, which was the only
private contribution to CIRM in the 2011-12 fiscal year. Both say
there was no connection between the donation last May 16 and the
StemCells, Inc., application, which was rejected by reviewers one
month earlier during closed-door meetings April 18-20, 2012.
from persons who have applied for funding or who intend to apply for
funding, but the rules do not speak to gifts from persons who lobby
on behalf of funding for others. The rules require that the governing
board of the agency be informed at a public meeting of gifts accepted
by Trounson on behalf of CIRM. Trounson is required to identify the
donor and conditions imposed by acceptance of the gift. Trounson did
neither prior to Klein's appearance last July on behalf of StemCells,
Inc.
recused himself from public discussions of the StemCells, Inc.,
application, although he did not offer an explanation. However, his
action was connected to his relationship with stem cell scientist Irv Weissman of
Stanford University, who founded the publicly traded company, currently sits on its board
and holds 124,608 shares of the firm. Trounson was a guest once at
Weissman's ranch for four days in July 2011, CIRM said in response to
a question this week.
for public communications, said last week that the agency plans to
report the donation to the governing board at its meeting in
the San Francisco Bay Area later this month.
the donation prior to the board's consideration of StemCells, Inc.'s,
application was “due to the lack of additional donations, a
transition in CIRM’s finance office and an oversight."(See thefull text of McCormack's statement here.)
the agency is concerned about the appearance of Klein's donation and
the subsequent board action, McCormack replied,
“No, the two items are entirely
separate with no connection. Item 1 involved Bob Klein making a
donation to allow science officers to attend a critically important
scientific meeting on stem cell research. The science officers had originally planned on attending but then were told they
could not because of cuts in our out-of-state travel budget – Bob
Klein’s donation, without using state funds, enabled the science
officers to attend. Item 2 is an ICOC (board) decision to fund
a research project that they felt had promise and was important for
the people of California.”
in the wake of his donation, the agency did not respond to inquiries
asking for an explanation.
an email that his donation was not connected to StemCells, Inc. He said that as late as June he had “no idea”
that the its application had been rejected by reviewers. Klein said that he committed to the donation
in “April or May.” (The full text of Klein's comments re the application can be found here and here.)
Prior to leaving CIRM in 2011, Klein was a non-voting member of the CIRM grant review committee, which consists of out-of-state scientists and seven CIRM board members. His service on the committee included the period when it approved a planning grant for StemCells, Inc., to prepare its application for the $20 million.
Klein noted that he did not pick the six science officers for the Japan trip. One of them was the lead science officer on the award round involving StemCells, Inc. A second was also heavily involved, according to the transcript of the July 2012 board meeting. Science officers, however, do not vote on or score applications. Klein characterized the CIRM staff as recommending against approval of the grant so “they were clearly not influenced” by his donation.
science officers were aimed at determining whether they believed the
cost of attending the stem cell convention justified what they
learned at the meeting. He said a second goal was to aid universities
and other researchers, mainly in Canada, “in advancing their
contributions from an existing donor or donors.” Canada is one of
CIRM's research partners.
Klein defended the involvement of
McEwen, who Klein said has contributed to the stem cell group conducting the meeting. Klein said McEwen does not engage in technical
discussions and added,
“On a conceptual basis it was
important for him to understand the spectrum of medical advances
towards therapies. His additional contributions to Canadian
non-profits could assist Canada in collaborating with California on
more international research, with California only funding the
research done in California and the donor helping to fund the
research done in Canada. No specific grant applications were
discussed. Finally, the discussion with the international partners
focuses on the funding process and funding collaboration it does not
discuss any individual.”
employees has stirred up controversy over the years in California.
The most recent example was Gov. Jerry Brown's much-reported trip to
China this spring, which was financed by private donations. Articles
in the Los Angeles Times and The Sacramento Bee both noted that
private funding arrangements have plenty of critics.
wrote,
“It just looks unseemly — a pack of lobbyists and other
favor-seekers paying big bucks to traipse after the governor,
schmoozing and gaining invaluable access.”
from Jock
O'Connell, international trade adviser for the economics
consulting firm Beacon Economics, who said,
“They're donating because they want
to curry favor with the incumbent administration."
donations for trips in the future, McCormack replied that the agency
is “always open to donations from generous supporters” provided
they meet the state's legal requirements.
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/FefPhO0IEiY/cash-and-favors-robert-klein-gives.html
- 001 International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- 002 CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- 003 International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- 004 MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- 005 CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- 006 Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 007 More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- 008 International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- 009 CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- 010 International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 011 Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- 012 US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- 013 International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- 014 An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- 015 International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- 016 Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- 017 CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- 018 International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- 019 International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- 020 Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- 021 New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- 022 Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- 023 OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- 024 International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- 025 International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 026 California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 027 International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- 028 Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- 029 International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- 030 Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- 031 Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 032 More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- 033 International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- 034 Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- 035 Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- 036 Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- 037 International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- 038 Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- 039 Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]
- 040 International Stem Cell Corporation - Breakthrough Technology Alert [Last Updated On: August 6th, 2010] [Originally Added On: August 6th, 2010]
- 041 Oxygen, hypoxia and the stem cell niche [Last Updated On: August 7th, 2010] [Originally Added On: August 7th, 2010]
- 042 Partnership Pays Off [Last Updated On: August 17th, 2010] [Originally Added On: August 17th, 2010]
- 043 Video: Summary of Recent Developments in Stem Cell and Regenerative Medicine from Kenneth Aldrich, Chairman of International Stem Cell Corporation [Last Updated On: August 18th, 2010] [Originally Added On: August 18th, 2010]
- 044 International Stem Cell Corporation Formalizes Stem Cell Based Eye Care Programs into Cytovis™ [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 045 International Stem cell Corporation Chairman Discusses Recent Stem Cell Research Funding Decision [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 046 International Stem Cell Corporation Not Adversely Affected by Stem Cell Research Funding Ban [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 047 A Primer on the Use of Stem Cells in Ophthalmology by Irving J. Arons [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 048 Kenneth Aldrich, Chairman and Co-Founder of International Stem Cell Corporation will be making two public appearances this week on behalf of ISCO. [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 049 International Stem Cell Corporation Reports Significant Progress Towards Creation of the First Bank of Immune-Matched Human Parthenogenetic Stem Cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 050 International Stem Cell Corporation and Insight Bioventures India Structure Indian Affiliate to Develop Stem Cell-Based Eye Care Therapeutics... [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 051 ISCO to Present Data on Progress of Human Parthenogenetic Stem Cell Differentiation into Functional Liver Cells at the Annual Meeting... [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 052 Putative tumor-initiating progenitor cells predict poor lung cancer prognosis [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 053 Therapeutic implications of colon CSCs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 054 Selective targeting of neuroblastoma tumour-initiating cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 055 Two Open Access reviews [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 056 Isolation and killing of candidate CML stem cells by antibody targeting [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 057 Some breast cancer tumors may not originate from stem cells? [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 058 On the low frequency of tumor-initiating cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 059 Must the last CML cell be killed? [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 060 Critical molecular pathways in CSCs of CML [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 061 Insights into the stem cells of CML [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 062 International Stem Cell Corporation Announces Launch Plans for New Skin Care Products [Last Updated On: October 16th, 2010] [Originally Added On: October 16th, 2010]
- 063 International Stem Cell Corporation Announces Completion of Its First Manufacturing Run of Lifeline Skin Care's Stem Cell-Based Skin Rejuvenation... [Last Updated On: October 26th, 2010] [Originally Added On: October 26th, 2010]
- 064 Notes from The Chairman Concerning ISCO Price Fluctuations [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 065 Heightened Interest from the Medical Research Community and New Funding of International Stem Cell Corporation's (ISCO) Therapeutic Research [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 066 International Stem Cell Corporation Announces the Commercial Launch of Its Breakthrough Stem Cell-Based Line of Skin Care Products [Last Updated On: December 10th, 2010] [Originally Added On: December 10th, 2010]
- 067 International Stem Cell Corporation Announces Commercial Sales to General Public of Its Breakthrough Stem Cell-Based Lines of Skin Care Products [Last Updated On: December 10th, 2010] [Originally Added On: December 10th, 2010]
- 068 International Stem Cell Corporation Announces $25 Million Common Stock Financing Agreement [Last Updated On: December 15th, 2010] [Originally Added On: December 15th, 2010]
- 069 International Stem Cell Corporation Announces Start of Marketing Collaboration with John Mauldin for Skin Care Products [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 070 International Stem Cell Corporation to Present Ethical and Technical Qualities of Human Parthenogenetic Stem Cells at the Center for Ethics in Science [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 071 Two new initiatives from the CSCC [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 072 A difference between normal and cancer SC biology in the nervous system [Last Updated On: January 7th, 2011] [Originally Added On: January 7th, 2011]
- 073 International Stem Cell Corporation Announces Company Update Conference Call [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 074 International Stem Cell Corporation Applauds Research Showing Parthenogenesis as a Potential Strategy for Treating Inherited Disease [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 075 International Stem Cell's Scientists in Collaboration with World Leading Stem Cell Experts Extend Understanding of Human Parthenogenetic Stem Cells... [Last Updated On: January 26th, 2011] [Originally Added On: January 26th, 2011]
- 076 International Stem Cell Corporation: A Multitude Of Potential Products From Its Parthenogenesis Technology by Jason Chew [Last Updated On: February 12th, 2011] [Originally Added On: February 12th, 2011]
- 077 International Stem Cell Corporation Demonstrates Progress in the Use of Immune Matched Human Parthenogenetic Stem Cells to Promote the Development... [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 078 International Stem Cell Corporation: Note From The CEO Andrey Semechkin [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 079 "A Little Egg On the Face" - LifeLine Skin Care Stem Cell Cream Article [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 080 International Stem Cell Corporation Updates on 2010 Initial Product Launch of its Lifeline Skin Care Products [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
